May 29 (Reuters) - Cocrystal Pharma Inc COCP.O:
COCRYSTAL PHARMA’S INVESTIGATIONAL DRUG CANDIDATE CC-42344 DEMONSTRATES STRONG ANTIVIRAL POTENCY AGAINST THE 2024 HIGHLY PATHOGENIC H5N1 AVIAN INFLUENZA STRAIN
Source text: ID:nGNX1vmqXg
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))